The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma-Reference-Cited by-同舟云学术

The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma

Published:2017-02 Issue:2 Volume:66 Page:338-346
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Pinato David J.,Sharma Rohini,Allara Elias,Yen Clarence,Arizumi Tadaaki,Kubota Keiichi,Bettinger Dominik,Jang Jeong Won,Smirne Carlo,Kim Young Woon,Kudo Masatoshi,Howell Jessica,Ramaswami Ramya,Burlone Michela E.,Guerra Vito,Thimme Robert,Ishizuka Mitsuru,Stebbing Justin,Pirisi Mario,Carr Brian I.

Publisher

Elsevier BV

Subject

Hepatology

Reference34 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Hepatocellular carcinoma–epidemiological trends and risk factors;Schutte;Dig Dis,2009

3. Novel advancements in the management of hepatocellular carcinoma in 2008;Llovet;J Hepatol,2008

4. Assessment of prognosis of cirrhosis;Durand;Semin Liver Dis,2008

5. Systematic review: The model for end-stage liver disease–should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis?;Cholongitas;Aliment Pharmacol Ther,2005

Cited by 308 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma;Molecular Cancer;2024-09-06

2. Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study;JHEP Reports;2024-09

3. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study;Frontiers in Immunology;2024-07-26

4. Evaluation and Management of Unresectable Hepatocellular Carcinoma: Multidisciplinary Indian Consensus Statements from a Delphi Panel;South Asian Journal of Cancer;2024-07-22

5. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment;Hepatology;2024-07-19